Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for Mild to Moderate COVID-19
NCT04323631Phase 1Withdrawn
- Sponsor
- Rambam Health Care Campus
- Start
- Apr 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rambam Health Care Campus. Primary endpoint: Number of patients developing severe infection or death at 28 days. Planned start Apr 2020; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04323631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323631.